Bhattacharyya Puja, Christopherson Richard I, Skarratt Kristen K, Chen Jake Z, Balle Thomas, Fuller Stephen J
Sydney Medical School Nepean, Faculty of Medicine and Health, The University of Sydney, Kingswood, NSW 2750, Australia.
Blacktown Hospital, Blacktown, NSW 2148, Australia.
Cancers (Basel). 2023 May 23;15(11):2881. doi: 10.3390/cancers15112881.
B cells are central to the adaptive immune response, providing long lasting immunity after infection. B cell activation is mediated by a cell surface B cell receptor (BCR) following recognition of an antigen. BCR signaling is modulated by several co-receptors including CD22 and a complex that contains CD19 and CD81. Aberrant signaling through the BCR and co-receptors promotes the pathogenesis of several B cell malignancies and autoimmune diseases. Treatment of these diseases has been revolutionized by the development of monoclonal antibodies that bind to B cell surface antigens, including the BCR and its co-receptors. However, malignant B cells can escape targeting by several mechanisms and until recently, rational design of antibodies has been limited by the lack of high-resolution structures of the BCR and its co-receptors. Herein we review recently determined cryo-electron microscopy (cryo-EM) and crystal structures of the BCR, CD22, CD19 and CD81 molecules. These structures provide further understanding of the mechanisms of current antibody therapies and provide scaffolds for development of engineered antibodies for treatment of B cell malignancies and autoimmune diseases.
B细胞对于适应性免疫反应至关重要,在感染后提供持久免疫力。B细胞活化是在识别抗原后由细胞表面B细胞受体(BCR)介导的。BCR信号传导由包括CD22以及包含CD19和CD81的复合物在内的几种共受体调节。通过BCR和共受体的异常信号传导促进了几种B细胞恶性肿瘤和自身免疫性疾病的发病机制。与B细胞表面抗原(包括BCR及其共受体)结合的单克隆抗体的开发彻底改变了这些疾病的治疗方法。然而,恶性B细胞可以通过多种机制逃避靶向,直到最近,抗体的合理设计一直受到BCR及其共受体缺乏高分辨率结构的限制。在此,我们综述了最近通过冷冻电子显微镜(cryo-EM)测定的BCR、CD22、CD19和CD81分子的晶体结构。这些结构进一步加深了我们对当前抗体疗法机制的理解,并为开发用于治疗B细胞恶性肿瘤和自身免疫性疾病的工程抗体提供了支架。